NIKKEI 225
38,923.03 +435.13 (+1.13%) HANG SENG
18,403.04 +323.43 (+1.79%) CRUDE OIL
74.14 -2.85 (-3.70%) GOLD FUTURES
2,368.60 +22.80 (+0.97%) DOW
38,571.03 -115.29 (-0.30%) Bitcoin GBP
54,192.25 +1,347.64 (+2.55%)
Nurix Therapeutics, Inc. (NRIX)
After hours:
| Previous close | 15.75 |
| Open | 16.20 |
| Bid | 16.03 x 400 |
| Ask | 16.10 x 100 |
| Day's range | 15.76 - 17.10 |
| 52-week range | 4.22 - 18.12 |
| Volume | |
| Avg. volume | 1,109,234 |
| Market cap | 980.133M |
| Beta (5Y monthly) | 2.10 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.66 |
| Earnings date | 11 Jul 2024 - 15 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 24.18 |
GlobeNewswireNurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present a corporate update at the Jefferies Global Healthcare Conference, at 5:30 p.m. ET on Wednesday, June 5, 2024, in New York City. The event will be
- GlobeNewswire
Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer
Expanded C-level team poised to accelerate development of NX-5948 in B cell malignanciesSAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointments of Paula G. O’Connor, M.D., as chief medical officer and Pasit Phiasivongsa, Ph.D., as chief technical officer of Nurix. “I am delighted
- GlobeNewswire
Nurix Therapeutics Announces Board Chair Transition
David L. Lacey steps down from chair role and will remain board member and retain committee leadership roles Current board member Julia P. Gregory unanimously elected new board chair SAN FRANCISCO, May 20, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the chair of its board of directors, David L. Lacey,
